Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) Products under Development by Stage of Development | 7 | 1 |
| Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) Products under Development by Therapy Area | 8 | 1 |
| Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) Products under Development by Indication | 9 | 1 |
| Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) Products under Development by Companies | 12 | 2 |
| Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) Therapeutics Assessment | 14 | 6 |
| Assessment by Monotherapy/Combination Products | 14 | 1 |
| Assessment by Mechanism of Action | 15 | 1 |
| Assessment by Route of Administration | 16 | 2 |
| Assessment by Molecule Type | 18 | 2 |
| Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) Companies Involved in Therapeutics Development | 20 | 3 |
| Paradigm Biopharmaceuticals Limited | 20 | 1 |
| Pfizer Inc. | 21 | 1 |
| Takeda Pharmaceutical Company Limited | 22 | 1 |
| Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) Drug Profiles | 23 | 7 |
| Pelladerm Drug Profile | 23 | 1 |
| pentosan polysulfate sodium Drug Profile | 24 | 2 |
| PF-152 Drug Profile | 26 | 1 |
| Small Molecules to Inhibit MMP for Myocardial Infarction Drug Profile | 27 | 1 |
| Small Molecules to Inhibit MMP-13 for Osteoarthritis Drug Profile | 28 | 1 |
| Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation Drug Profile | 29 | 1 |
| Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) Dormant Projects | 30 | 1 |
| Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) Discontinued Products | 31 | 1 |
| Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) Featured News &Press Releases | 32 | 8 |
| Sep 16, 2016: Preclinical study underpins efficacy of Paradigms Rhinosul for hay fever treatment | 32 | 1 |
| Sep 07, 2016: Paradigm s PPS as a potential breakthrough in t he treatment of viral arthritis and joint pain | 32 | 2 |
| Aug 19, 2016: Market update Paradigm s PPS nasal spray to treat Allergic Rhinitis (Hay Fever) | 34 | 1 |
| Mar 02, 2016: Paradigm initiates second clinical trial site to investigate ZILOSUL as a treatment for bone bruising following Anterior Cruciate Ligament (ACL) injury | 35 | 1 |
| Feb 25, 2016: First participant in Paradigm s clinical trial starts ZILOSUL treatment for bone bruising following Anterior Cruciate Ligament (ACL) injury | 36 | 1 |
| Feb 23, 2016: Paradigm starts clinical trial to investigate ZILOSUL as a treatment for bone bruising following Anterior Cruciate Ligament (ACL) injury | 36 | 1 |
| Dec 03, 2015: Elite athlete from a major sporting code treated with Paradigm s ZILOSUL under the Therapeutic Goods Administration s Special Access Scheme | 37 | 1 |
| Nov 23, 2015: Paradigm s ZILOSUL approved for clinical trial | 38 | 2 |
| Appendix | 40 | 2 |
| Methodology | 40 | 1 |
| Coverage | 40 | 1 |
| Secondary Research | 40 | 1 |
| Primary Research | 40 | 1 |
| Expert Panel Validation | 40 | 1 |
| Contact Us | 40 | 1 |
| Disclaimer | 41 | 1 |